HK1201040A1 - 治療骨質疏鬆症的方法 - Google Patents
治療骨質疏鬆症的方法Info
- Publication number
- HK1201040A1 HK1201040A1 HK15100984.1A HK15100984A HK1201040A1 HK 1201040 A1 HK1201040 A1 HK 1201040A1 HK 15100984 A HK15100984 A HK 15100984A HK 1201040 A1 HK1201040 A1 HK 1201040A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- treating osteoporosis
- osteoporosis
- treating
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/916—Hydrolases (3) acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/10—Musculoskeletal or connective tissue disorders
- G01N2800/108—Osteoporosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Quinoline Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161538039P | 2011-09-22 | 2011-09-22 | |
PCT/US2012/056281 WO2013043840A1 (en) | 2011-09-22 | 2012-09-20 | Method for treating osteoporosis |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1201040A1 true HK1201040A1 (zh) | 2015-08-21 |
Family
ID=47010756
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK15100984.1A HK1201040A1 (zh) | 2011-09-22 | 2015-01-28 | 治療骨質疏鬆症的方法 |
Country Status (19)
Country | Link |
---|---|
US (1) | US10166225B2 (zh) |
EP (2) | EP3275443A1 (zh) |
JP (1) | JP6240075B2 (zh) |
KR (1) | KR20140069133A (zh) |
CN (1) | CN103957915A (zh) |
AR (1) | AR087995A1 (zh) |
AU (1) | AU2012312364B2 (zh) |
BR (1) | BR112014006702A2 (zh) |
CA (1) | CA2848512A1 (zh) |
EA (1) | EA201490676A1 (zh) |
ES (1) | ES2639093T3 (zh) |
GE (1) | GEP201606523B (zh) |
HK (1) | HK1201040A1 (zh) |
IL (1) | IL231495B (zh) |
MX (1) | MX351133B (zh) |
TW (1) | TWI564009B (zh) |
UA (1) | UA115866C2 (zh) |
WO (1) | WO2013043840A1 (zh) |
ZA (1) | ZA201401728B (zh) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2995880C (en) | 2009-01-16 | 2021-01-05 | Exelixis, Inc. | Processes for preparing n-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-n'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide |
DK2621481T4 (da) | 2010-09-27 | 2023-01-09 | Exelixis Inc | Dobbelte inhibitorer af MET og VEGF til behandling af kastrationsresistent prostatacancer og osteoblastiske knoglemetastaser |
TW201309650A (zh) | 2011-02-10 | 2013-03-01 | Exelixis Inc | 製造喹啉化合物之方法及包含該化合物之醫藥組合物 |
US20120252840A1 (en) | 2011-04-04 | 2012-10-04 | Exelixis, Inc. | Method of Treating Cancer |
BR212013028314U2 (pt) | 2011-05-02 | 2015-11-03 | Exelixis Inc | método para tratar câncer e dor de câncer de osso |
UA115866C2 (uk) | 2011-09-22 | 2018-01-10 | Екселіксіс, Інк. | Спосіб лікування остеопорозу |
HUE048023T2 (hu) | 2011-10-20 | 2020-05-28 | Exelixis Inc | Eljárás kinolin-származékok elõállítására |
JP2015515988A (ja) | 2012-05-02 | 2015-06-04 | エクセリクシス, インク. | 溶骨性骨転移を治療するためのmet−vegf二重調節剤 |
NZ712330A (en) | 2013-03-15 | 2020-04-24 | Exelixis Inc | Metabolites of n-(4-{ [6,7-bis(methyloxy)quinolin-4-yl]oxy} phenyl)-n’-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide |
US11564915B2 (en) | 2013-04-04 | 2023-01-31 | Exelixis, Inc. | Cabozantinib dosage form and use in the treatment of cancer |
BR112016018450A2 (pt) | 2014-02-14 | 2018-09-18 | Exelixis Inc | formas sólidas cristalinas de n-{4-[(6,7-dimetoxiquinolin-4-il)oxi]fenil}-n'-(4-fluorofenil)ciclopropano-1,1-dicarboxamida, processos de preparo e métodos de uso |
EP3119476A1 (en) | 2014-03-17 | 2017-01-25 | Exelixis, Inc. | Dosing of cabozantinib formulations |
CN104788372B (zh) * | 2014-07-25 | 2018-01-30 | 上海圣考医药科技有限公司 | 一种氘代卡博替尼衍生物、其制备方法、应用及其中间体 |
ES2929888T3 (es) * | 2014-07-31 | 2022-12-02 | Exelixis Inc | Procedimiento para preparar cabozantinib marcado con flúor 18 y sus análogos |
BR112017002318A2 (pt) | 2014-08-05 | 2018-07-17 | Exelixis, Inc. | combinações de fármacos para tratar mieloma múltiplo. |
WO2017181187A1 (en) | 2016-04-15 | 2017-10-19 | Exelixis, Inc. | Method of treating renal cell carcinoma using n-(4-(6,7-dimethoxyquinolin-4-yloxy) phenyl)-n'-(4-fluoropheny)cyclopropane-1,1-dicarboxamide, (2s)-hydroxybutanedioate |
EP3630726B1 (en) | 2017-05-26 | 2021-12-22 | Exelixis, Inc. | Crystalline solid forms of salts of n-{4-[(6,7-dimethoxyquinolin-4-yl) oxy]phenyl}-n'-(4-fluorphenyl) cyclopropane-1,1-dicarboxamide, processes for making, and methods of use |
CN111757735B (zh) | 2018-01-26 | 2023-09-22 | 埃克塞里艾克西斯公司 | 用于治疗激酶依赖性病症的化合物 |
US20220152274A1 (en) * | 2020-11-19 | 2022-05-19 | University Of Massachusetts | Demineralized bone paper |
Family Cites Families (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4107288A (en) | 1974-09-18 | 1978-08-15 | Pharmaceutical Society Of Victoria | Injectable compositions, nanoparticles useful therein, and process of manufacturing same |
US5145684A (en) | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
US20040266771A1 (en) * | 2001-06-29 | 2004-12-30 | Alain Moussy | Use of tyrosine kinase inhibitors for treating bone loss |
CA2537812C (en) | 2003-09-26 | 2013-01-22 | Exelixis, Inc. | C-met modulators and method of use |
WO2006014325A2 (en) | 2004-07-02 | 2006-02-09 | Exelixis, Inc. | C-met modulators and method of use |
JP4572269B2 (ja) * | 2004-11-25 | 2010-11-04 | 財団法人ヒューマンサイエンス振興財団 | 癌の骨転移のリスクの予測方法 |
WO2006108059A1 (en) | 2005-04-06 | 2006-10-12 | Exelixis, Inc. | C-met modulators and methods of use |
EP2056829B9 (en) | 2006-08-16 | 2012-09-26 | Exelixis, Inc. | Using pi3k and mek modulators in treatments of cancer |
WO2008044379A1 (fr) * | 2006-10-11 | 2008-04-17 | Oriental Yeast Co., Ltd. | Modèle animal de perte osseuse |
WO2008076415A1 (en) | 2006-12-14 | 2008-06-26 | Exelixis, Inc. | Methods of using mek inhibitors |
WO2008083319A1 (en) | 2006-12-29 | 2008-07-10 | Il Yang Pharmaceutical Company, Ltd. | Solid state forms of enantiopure ilaprazole |
DE602008006700D1 (zh) * | 2007-03-02 | 2011-06-16 | Novartis Ag | |
EP2164329A4 (en) * | 2007-05-08 | 2010-11-17 | Burnham Inst Medical Research | NON-TISSUE-SPECIFIC ALKALI PHOSPHATASE INHIBITORS AND THEIR USE FOR THE TREATMENT OF VASCULAR SCALES |
CL2008002775A1 (es) * | 2007-09-17 | 2008-11-07 | Amgen Inc | Uso de un agente de unión a esclerostina para inhibir la resorción ósea. |
US20110044978A1 (en) * | 2007-12-14 | 2011-02-24 | Amgen Inc. | Method for treating bone fracture |
JP5010034B2 (ja) * | 2007-12-28 | 2012-08-29 | エフ.ホフマン−ラ ロシュ アーゲー | 生理学的状態の評価 |
UY31800A (es) | 2008-05-05 | 2009-11-10 | Smithkline Beckman Corp | Metodo de tratamiento de cancer usando un inhibidor de cmet y axl y un inhibidor de erbb |
UY32142A (es) | 2008-09-26 | 2010-05-31 | Smithkline Beckman Corp | Preparación de una quinoliniloxidifenilciclopropanodicarboxamida |
AU2009300328A1 (en) * | 2008-10-01 | 2010-04-08 | Ludwig Institute For Cancer Research | Methods for the treatment of cancer |
CN102282134B (zh) | 2008-11-13 | 2015-04-01 | 埃克塞里艾克西斯公司 | 喹啉衍生物制备方法 |
TW201028383A (en) | 2008-12-04 | 2010-08-01 | Exelixis Inc | Methods of preparing quinoline derivatives |
CA2995880C (en) | 2009-01-16 | 2021-01-05 | Exelixis, Inc. | Processes for preparing n-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-n'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide |
KR20120051702A (ko) | 2009-07-17 | 2012-05-22 | 엑셀리시스, 인코포레이티드 | N-〔3-플루오로-4-({6-(메틸옥시)-7-〔(3-모르폴린-4-일프로필)옥시〕퀴놀린-4-일}옥시)페닐〕-n''-(4-플루오로페닐)시클로프로판-1,1-디카르복사미드의 결정형 |
UA108618C2 (uk) | 2009-08-07 | 2015-05-25 | Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку | |
KR20130038206A (ko) | 2010-03-12 | 2013-04-17 | 엑셀리시스, 인코포레이티드 | N-〔3-플루오로-4-({6-(메틸옥시)-7-〔(3-모폴린-4-일프로필)옥시〕-퀴놀린-4-일}옥시)페닐〕-n’-(4-플루오로페닐)사이클로프로판-1,1-디카복사미드의 수화된 결정형 형태 |
US20120070368A1 (en) | 2010-04-16 | 2012-03-22 | Exelixis, Inc. | Methods of Using C-Met Modulators |
ES2904646T3 (es) | 2010-07-16 | 2022-04-05 | Exelixis Inc | Composiciones farmacéuticas moduladoras de c-Met |
EP2593091A1 (en) | 2010-07-16 | 2013-05-22 | Exelixis, Inc. | C-met modulator pharmaceutical compositions |
SG10201408229WA (en) * | 2010-08-31 | 2015-02-27 | Genentech Inc | Biomarkers and methods of treatment |
DK2621481T4 (da) * | 2010-09-27 | 2023-01-09 | Exelixis Inc | Dobbelte inhibitorer af MET og VEGF til behandling af kastrationsresistent prostatacancer og osteoblastiske knoglemetastaser |
EP2621483A1 (en) | 2010-09-27 | 2013-08-07 | Exelixis, Inc. | Dual inhibitors of met and vegf for the treatment of castration resistant prostate cancer and osteoblastic bone metastases |
US20140066444A1 (en) | 2010-09-27 | 2014-03-06 | Exelixis, Inc. | Method of Treating Cancer |
JP2013543011A (ja) | 2010-11-22 | 2013-11-28 | グラクソスミスクライン、インテレクチュアル、プロパティー、ナンバー2、リミテッド | 癌の治療法 |
TW201309650A (zh) | 2011-02-10 | 2013-03-01 | Exelixis Inc | 製造喹啉化合物之方法及包含該化合物之醫藥組合物 |
US20120252840A1 (en) | 2011-04-04 | 2012-10-04 | Exelixis, Inc. | Method of Treating Cancer |
BR212013028314U2 (pt) * | 2011-05-02 | 2015-11-03 | Exelixis Inc | método para tratar câncer e dor de câncer de osso |
TW201306842A (zh) | 2011-06-15 | 2013-02-16 | Exelixis Inc | 使用pi3k/mtor吡啶並嘧啶酮抑制劑及苯達莫司汀及/或利妥昔單抗治療惡性血液疾病之組合療法 |
UA115866C2 (uk) | 2011-09-22 | 2018-01-10 | Екселіксіс, Інк. | Спосіб лікування остеопорозу |
HUE048023T2 (hu) | 2011-10-20 | 2020-05-28 | Exelixis Inc | Eljárás kinolin-származékok elõállítására |
WO2013070890A1 (en) | 2011-11-08 | 2013-05-16 | Exelixis, Inc. | Dual inhibitor of met and vegf for treating cancer |
AR088813A1 (es) | 2011-11-08 | 2014-07-10 | Exelixis Inc | Metodo para cuantificar el tratamiento de cancer |
JP2015515988A (ja) | 2012-05-02 | 2015-06-04 | エクセリクシス, インク. | 溶骨性骨転移を治療するためのmet−vegf二重調節剤 |
ES2726605T3 (es) | 2012-09-07 | 2019-10-08 | Exelixis Inc | Inhibidores de MET, VEGFR y RET para usar en el tratamiento del adenocarcinoma de pulmón |
-
2012
- 2012-09-20 UA UAA201404224A patent/UA115866C2/uk unknown
- 2012-09-20 US US14/346,570 patent/US10166225B2/en active Active
- 2012-09-20 AU AU2012312364A patent/AU2012312364B2/en active Active
- 2012-09-20 JP JP2014531955A patent/JP6240075B2/ja active Active
- 2012-09-20 CA CA2848512A patent/CA2848512A1/en not_active Abandoned
- 2012-09-20 KR KR1020147009534A patent/KR20140069133A/ko not_active Application Discontinuation
- 2012-09-20 GE GEAP201213446A patent/GEP201606523B/en unknown
- 2012-09-20 CN CN201280051094.4A patent/CN103957915A/zh active Pending
- 2012-09-20 EP EP17173155.7A patent/EP3275443A1/en not_active Withdrawn
- 2012-09-20 BR BR112014006702A patent/BR112014006702A2/pt active Search and Examination
- 2012-09-20 EA EA201490676A patent/EA201490676A1/ru unknown
- 2012-09-20 EP EP12770368.4A patent/EP2758057B1/en active Active
- 2012-09-20 WO PCT/US2012/056281 patent/WO2013043840A1/en active Application Filing
- 2012-09-20 MX MX2014003027A patent/MX351133B/es active IP Right Grant
- 2012-09-20 ES ES12770368.4T patent/ES2639093T3/es active Active
- 2012-09-21 AR ARP120103501A patent/AR087995A1/es unknown
- 2012-09-21 TW TW101134829A patent/TWI564009B/zh active
-
2014
- 2014-03-10 ZA ZA2014/01728A patent/ZA201401728B/en unknown
- 2014-03-12 IL IL231495A patent/IL231495B/en active IP Right Grant
-
2015
- 2015-01-28 HK HK15100984.1A patent/HK1201040A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
US20140228401A1 (en) | 2014-08-14 |
TW201313232A (zh) | 2013-04-01 |
AU2012312364A1 (en) | 2014-04-10 |
UA115866C2 (uk) | 2018-01-10 |
EP2758057B1 (en) | 2017-05-31 |
MX2014003027A (es) | 2014-10-24 |
AR087995A1 (es) | 2014-04-30 |
JP6240075B2 (ja) | 2017-11-29 |
BR112014006702A2 (pt) | 2017-06-13 |
EP3275443A1 (en) | 2018-01-31 |
NZ622722A (en) | 2016-09-30 |
EA201490676A1 (ru) | 2015-02-27 |
CA2848512A1 (en) | 2013-03-28 |
IL231495A0 (en) | 2014-04-30 |
TWI564009B (zh) | 2017-01-01 |
US10166225B2 (en) | 2019-01-01 |
MX351133B (es) | 2017-10-03 |
ES2639093T3 (es) | 2017-10-25 |
CN103957915A (zh) | 2014-07-30 |
AU2012312364B2 (en) | 2017-11-09 |
ZA201401728B (en) | 2016-01-27 |
WO2013043840A1 (en) | 2013-03-28 |
IL231495B (en) | 2019-03-31 |
JP2014527984A (ja) | 2014-10-23 |
KR20140069133A (ko) | 2014-06-09 |
GEP201606523B (en) | 2016-08-10 |
EP2758057A1 (en) | 2014-07-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1201040A1 (zh) | 治療骨質疏鬆症的方法 | |
PL2685961T3 (pl) | Sposób leczenia urazu neurologicznego | |
ZA201400005B (en) | Method for treating eczema | |
EP2698463A4 (en) | WASHING METHOD | |
GB201118838D0 (en) | Process for treating an underground formation | |
ZA201208219B (en) | Method for treating wasterwater | |
EP2531625A4 (en) | PROCESS FOR PROCESSING FRACTURE MATERIALS | |
PL2771280T3 (pl) | Sposób obróbki skał fosfatowych | |
EP2650276A4 (en) | PROCESS FOR PRODUCTION OF -FLUOROALCOOL | |
EP2716970A4 (en) | WASTE MELTING PROCESS | |
HRP20181649T1 (hr) | Metoda liječenja osteoporoze | |
HK1202297A1 (zh) | 治療痤瘡的方法 | |
PL2691219T3 (pl) | Sposób obróbki tekstyliów technicznych | |
HK1252353A1 (zh) | 治療精神分裂症的方法 | |
EP2723348A4 (en) | METHOD FOR THE TREATMENT OF ADIPOSITAS | |
EP2694077A4 (en) | METHOD FOR TREATING ASTHENOPY | |
GB201101219D0 (en) | Method | |
IL228744A0 (en) | A method for treating diseases related to interferon alpha | |
GB201121008D0 (en) | Apparatus & method | |
IL233240A0 (en) | A device for treating cuts | |
EP2676746A4 (en) | straightening PROCEDURE | |
GB201105523D0 (en) | Treatment method | |
GB201111670D0 (en) | Method & apparatus | |
GB201119967D0 (en) | Method | |
GB201114347D0 (en) | Method |